ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
19.95
-0.34 (-1.68%)
Feb 21, 2025, 4:00 PM EST - Market closed
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for ACADIA Pharmaceuticals stock have an average target of 25.33, with a low estimate of 19 and a high estimate of 39. The average target predicts an increase of 26.97% from the current stock price of 19.95.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Hold | 6 | 7 | 7 | 7 | 7 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Hold Initiates $22 | Hold | Initiates | $22 | +10.28% | Feb 11, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades $20 | Strong Buy → Hold | Downgrades | $20 | +0.25% | Jan 3, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +40.35% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +35.34% | Nov 7, 2024 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 10, 2024 |
Financial Forecast
Revenue This Year
994.35M
from 726.44M
Increased by 36.88%
Revenue Next Year
1.07B
from 994.35M
Increased by 8.01%
EPS This Year
0.72
from -0.37
EPS Next Year
0.74
from 0.72
Increased by 2.60%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.2B | 1.4B | |||
| Avg | 994.4M | 1.1B | 1.2B | |||
| Low | 928.6M | 982.9M | 1.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 53.2% | 18.0% | 27.8% | |||
| Avg | 36.9% | 8.0% | 10.6% | |||
| Low | 27.8% | -1.2% | -4.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.23 | 1.31 | 2.36 | |||
| Avg | 0.72 | 0.74 | 1.13 | |||
| Low | 0.39 | 0.24 | 0.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 81.5% | 218.4% | |||
| Avg | - | 2.6% | 52.9% | |||
| Low | - | -67.5% | -43.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.